Clinical effectiveness of stress-reduction techniques in patients with hypertension: Systematic reviewand meta-analysis

Journal of Hypertension

Volumn 32, Issue 10, 2014, Pages 1936-1944

  Nagele, Eva ^a   Jeitler, Klaus ^a   Horvath, Karl ^a   Semlitsch, Thomas ^a,b   Posch, Nicole ^a   Herrmann, Kirsten H ^c,d   Grouven, Ulrich ^c,e   Hermanns, Tatjana ^c   Hemkens, Lars G ^c,f   Siebenhofer, Andrea ^g  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b JOANNEUM RESEARCH   (Austria)

^c INSTITUTE FOR QUALITY AND EFFICIENCY IN HEALTH CARE IQWIG   (Germany)

^d Bristol Meyers Squibb   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

^g GOETHE UNIVERSITY   (Germany)

Author keywords

Hypertension; Relaxation therapy; Stress management; Stress reduction techniques; Systematic review

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR MORTALITY; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; DIASTOLIC BLOOD PRESSURE; END STAGE RENAL DISEASE; FEEDBACK SYSTEM; FOLLOW UP; HUMAN; HYPERTENSION; META ANALYSIS; MORBIDITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAXATION TRAINING; REVIEW; STRESS; STRESS MANAGEMENT; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; ADULT; BLOOD PRESSURE; COMPLICATION; DRUG EFFECTS; HARM REDUCTION; KIDNEY FAILURE, CHRONIC; MENTAL STRESS; MORTALITY; TREATMENT OUTCOME;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HARM REDUCTION; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; QUALITY OF LIFE; STRESS, PSYCHOLOGICAL; TREATMENT OUTCOME;

EID: 84925706422     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000298     Document Type: Review

References (80)

1. World Health Organisation (WHO). Chronic disease: key risk factors include high cholesterol, high blood pressure, low fruit and vegetable intake. 2003. http://www.who.int/entity/dietphysicalactivity/media/ en/gsfs-chronic-disease.pdf. [cited 12 December 2011]
2. World Health Organisation (WHO). Global atlas on cardiovascular disease prevention and control. 2011. http://whqlibdoc.who.int/publi cations/2011/9789241564373-eng.pdf. [cited 12 December 2011]
3. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347:305-313.
4. Strazzullo P, D'Elia L, Kandala NB, Cappuccio FP. Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. BMJ 2009; 339:b4567.
5. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002; 162:1867-1872.
6. Woodward M, Lam TH, Barzi F, Patel A, Gu D, Rodgers A, et al. Smoking, quitting, and the risk of cardiovascular disease among women and men in the Asia-Pacific region. Int J Epidemiol 2005; 34:1036-1045.
7. Figueredo VM. The time has come for physicians to take notice: the impact of psychosocial stressors on the heart. Am J Med 2009; 122:704-712.
8. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 1999; 99:2192-2217.
9. Rosengren A, Hawken S, Ounpuu S, Sliwa K, Zubaid M, Almahmeed WA, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:953-962.
10. Dimsdale JE. Psychological stress and cardiovascular disease. J Am Coll Cardiol 2008; 51:1237-1246.
11. Goldstein DS, Kopin IJ. Evolution of concepts of stress. Stress 2007; 10:109-120.
12. Goldstein I, Shapiro D, Thananopavarn C, Sambhi M. Comparison of drug and behavioral treatments of essential hypertension. Health Psychol 1982; 1:7-26.
13. Siegrist J. Psychosoziale Einflüsse auf Entstehung und Verlauf der koronaren Herzerkrankung. Herz 2001; 26:316-325.
14. Brotman DJ, Golden SH, Wittstein IS. The cardiovascular toll of stress. Lancet 2007; 370:1089-1100.
15. Yan LL, Liu K, Matthews KA, Daviglus ML, Ferguson TF, Kiefe CI. Psychosocial factors and risk of hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) study. JAMA 2003; 290:2138-2148.
16. Arzneimittelkommission der deutschenÄrzteschaft. Empfehlungen zur Therapie der arteriellen Hypertonie. Arzneiverordnung in der Praxis 2004; 31(Sonderheft 2 Therapieempfehlungen):1-30.
17. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
18. Deutsche Hochdruckliga, Deutsche Hypertonie Gesellschaft. Leitlinien zur Behandlung der arteriellen Hypertonie. 2008. http://www.uniduesseldorf. de/AWMF/ll/046-001.pdf. [cited 12 January 2011]
19. European Society of Hypertension, European Society of Cardiology. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
20. Rabi DM, Daskalopoulou SS, Padwal RS, Khan NA, Grover SA, Hackam DG, et al. The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol 2011; 27:415-433; e1-2.
21. National Institute for Health and Clinical Excellence. Hypertension: the clinical management of primary hypertension in adults. NICE clinical guidelines 2011. http://www.nice.org.uk/nicemedia/live/13561/56007/ 56007.pdf. [cited 23 August 2013]
22. Institute for Quality and Efficiency in healthcare. General methods. Version 3.0. 2008. https://www.iqwig.de/download/IQWiG-General- methods-V-3-0.pdf. [cited 12 January 2011]
23. Institute for Quality and Efficiency in healthcare. Responsibilities and objectives of IQWIG. 2011. https://www.iqwig.de/en/about-us/ responsibilities-and-objectives-of-iqwig.2946.html. [cited 6 December 2013]
24. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Nutzenbewertung nichtmedikamentöser Behandlungsstrategien bei Patienten mit Bluthochdruck: Gewichtsreduktion; Abschlussbericht; Auftrag A05/21A. IQWiG-Berichte 2006. http://www.iqwig.de/down load/A05-21A-Abschlussbericht-Gewichtsreduktion-bei-Bluthoch druck-neu.pdf. [cited 12 January 2011]
25. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Nutzenbewertung nichtmedikamentöser Behandlungsstrategien bei Patienten mit essenzieller Hypertonie: Kochsalzreduktion; Rapid Report; Auftrag A05-21B. IQWiG-Berichte 2009. http://www.iqwig. de/download/A05-21B-Rapid-Report-Nichtmedikamentoese-Behand lungsstrategien-bei-Hypertonie-Kochsalzreduktion.pdf. [cited 12 January 2011]
26. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Nutzenbewertung nichtmedikamentöser Behandlungsstrategien bei Patienten mit essenzieller Hypertonie: Steigerung der körperlichen Aktivität; Rapid Report; Auftrag A05-21D. IQWiG-Berichte 2010. http://www.iqwig.de/download/A05-21D-Rapid-Report-Nichtmedik amentoese-Behandlungsstrategien-bei-Hypertonie-Steigerung-der- koerperlichen-Aktivitaet.pdf. [cited 12 January 2011]
27. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Nutzenbewertung nichtmedikamentöser Behandlungsstrategien bei Patienten mit Bluthochdruck: Reduktion des Alkoholkonsums; Rapid Report; Auftrag A05/21E. IQWiG-Berichte 2012. https://www.iqwig.de/ download/A05-21E-Rapid-Report-Reduktion-des-Alkoholkonsums- bei-Hypertonie.pdf. [cited 23 August 2013]
28. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Nutzenbewertung nichtmedikamentöser Behandlungsstrategien bei Patienten mit Bluthochdruck: Rauchverzicht; Rapid Report; Auftrag A05/21G. IQWiG-Berichte 2012. https://www.iqwig.de/download/ A05-21G-Rapid-Report-Nichtmedikamentoese-Behandlungsstrategien- bei-Hypertonie-Rauchverzicht.pdf. [cited 23 August 2013]
29. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Nutzenbewertung nichtmedikamentöser Behandlungsstrategien bei Patienten mit Bluthochdruck: Spezielle Ernährungsformen ohne primär körpergewichts-oder kochsalzreduzierende Intention; Rapid Report; Auftrag A05/21C. IQWiG-Berichte 2012. https://www.iqwig.de/ download/A05-21C-RR-Spezielle-Ernaehrungsformen-bei-Hyperto nie.pdf. [cited 23 August 2013]
30. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Nutzenbewertung nichtmedikamentöser Behandlungsstrategien bei Patienten mit essenzieller Hypertonie: Stressbewältigungsmaßnah men; Rapid Report; Auftrag A05-21F. IQWiG-Berichte https://www. iqwig.de/a05-21f-stressbewaeltigungsmassnahmen-bei.986.html?tid= 1299. [cited 4 November 2011]
31. Horvath K, Jeitler K, Siering U, Stich AK, Skipka G, Gratzer TW, et al. Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis. Arch Intern Med 2008; 168:571-580.
32. Matyas E, Jeitler K, Horvath K, Semlitsch T, Hemkens LG, Pignitter N, et al. Benefit assessment of salt reduction in patients with hypertension: systematic overview. J Hypertens 2011; 29:821-828.
33. Siebenhofer A, Horvath K, Jeitler K, Berghold A, Stich AK, Matyas E, et al. Long-term effects of weight-reducing drugs in hypertensive patients. Cochrane Database Syst Rev 2009; CD007654.
34. Semlitsch T, Jeitler K, Hemkens LG, Horvath K, Nagele E, Schuermann C, et al. Increasing physical activity for the treatment of hypertension: a systematic review and meta-analysis. Sports Med 2013; 43:1009-1023.
35. Siebenhofer A, Jeitler K, Berghold A, Waltering A, Hemkens LG, Semlitsch T, et al. Long-term effects of weight-reducing diets in hypertensive patients. Cochrane Database Syst Rev 2011; 9:CD008274.
36. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and metaanalyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339:b2700.
37. Becker LA, Oxman AD. Chapter 22: overviews of reviews. Cochrane Handbook for Systematic Reviews of Interventions Version 501. 2008. http://www.cochrane-handbook.org/. [cited 16 February 2010]
38. Oxman AD, Guyatt GH. Validation of an index of the quality of review articles. J Clin Epidemiol 1991; 44:1271-1278.
39. Oxman AD, Guyatt GH, Singer J, Goldsmith CH, Hutchison BG, Milner RA, et al. Agreement among reviewers of review articles. J Clin Epidemiol 1991; 44:91-98.
40. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188.
41. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-560.
42. Ospina MB, Bond K, Karkhaneh M, Buscemi N, Dryden DM, Barnes V, et al. Clinical trials of meditation practices in healthcare: characteristics and quality. J Altern Complement Med 2008; 14:1199-1213.
43. Ospina MB, Bond K, Karkhaneh M, Tjosvold L, Vandermeer B, Liang Y, et al. Meditation practices for health: state of the research. Evid Rep Technol Assess (Full Rep) 2007;1-263.
44. Lee MS, Pittler MH, Guo R, Ernst E. Qigong for hypertension: a systematic review of randomized clinical trials. J Hypertens 2007; 25:1525-1532.
45. Greenhalgh J, Dickson R, Dundar Y. The effects of biofeedback for the treatment of essential hypertension: a systematic review. Health Technol Assess 2009; 13:1-104.
46. Greenhalgh J, Dickson R, Dundar Y. Biofeedback for hypertension: a systematic review. J Hypertens 2010; 28:644-652.
47. Dickinson HO, Mason JM, Nicolson DJ, Campbell F, Beyer FR, Cook JV, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens 2006; 24:215-233.
48. Dickinson H, Campbell F, Beyer F, Nicolson D, Cook J, Ford G, et al. Relaxation therapies for the management of primary hypertension in adults: a Cochrane review. J Hum Hypertens 2008; 22:809-820.
49. Dickinson HO, Campbell F, Beyer FR, Nicolson DJ, Cook JV, Ford GA, et al. Relaxation therapies for the management of primary hypertension in adults. Cochrane Database Syst Rev 2008; CD004935.
50. Ng BH, Tsang HW. Psychophysiological outcomes of health qigong for chronic conditions: a systematic review. Psychophysiology 2009; 46:257-269.
51. Canter PH, Ernst E. Insufficient evidence to conclude whether or not transcendental meditation decreases blood pressure: results of a systematic review of randomized clinical trials. J Hypertens 2004; 22:2049-2054.
52. Guo X, Zhou B, Nishimura T, Teramukai S, Fukushima M. Clinical effect of qigong practice on essential hypertension: a meta-analysis of randomized controlled trials. J Altern Complement Med 2008; 14:27-37.
53. Nakao M, Yano E, Nomura S, Kuboki T. Blood pressure-lowering effects of biofeedback treatment in hypertension: a meta-analysis of randomized controlled trials. Hypertens Res Clin Exp 2003; 26:37-46.
54. Yucha CB, Clark L, Smith M, Uris P, LaFleur B, Duval S. The effect of biofeedback in hypertension. Appl Nurs Res 2001; 14:29-35.
55. Anderson JW, Liu C, Kryscio RJ. Blood pressure response to transcendental meditation: a meta-analysis. Am J Hypertens 2008; 21:310-316.
56. Modesti PA, Ferrari A, Bazzini C, Costanzo G, Simonetti I, Taddei S, et al. Psychological predictors of the antihypertensive effects of musicguided slow breathing. J Hypertens 2010; 28:1097-1103.
57. Nord AL, Kjellgren K, Ekman I. Effect of device-guided slow breathing in long-term treatment of hypertension. Eur Heart J 2010; 31 ((suppl 1)): 297-587; (Abstract p.532).
58. Nord L, Ekman I, Kjellgren KI. Effects of slow breathing exercises and music in patients with hypertension: 15 months follow-up of personcentered medicine in action. Int J Pers Cent Med 2012; 2:377-383.
59. Patel C, Marmot M. Can general practitioners use training in relaxation and management of stress to reduce mild hypertension? Br Med J (Clin Res Ed) 1988; 296:21-24.
60. Schein MH, Gavish B, Herz M, Rosner-Kahana D, Naveh P, Knishkowy B, et al. Treating hypertension with a device that slows and regularises breathing: a randomised, double-blind controlled study. J Hum Hypertens 2001; 15:271-278.
61. Shapiro D, Hui KK, Oakley ME, Pasic J, Jamner LD. Reduction in drug requirements for hypertension by means of a cognitive-behavioral intervention. Am J Hypertens 1997; 10:9-17.
62. Agras WS, Southam MA, Taylor CB. Long-term persistence of relaxation-induced blood pressure lowering during the working day. J Consult Clin Psychol 1983; 51:792-794.
63. Southam MA, Agras WS, Taylor CB, Kraemer HC. Relaxation training. Blood pressure lowering during the working day. Arch Gen Psychiatry 1982; 39:715-717.
64. Blanchard EB, Eisele G, Gordon MA, Cornish PJ, Wittrock DA, Gilmore L, et al. Thermal biofeedback as an effective substitute for sympatholytic medication in moderate hypertension: a failure to replicate. Biofeedback Self Regul 1993; 18:237-253.
65. Agras WS, Taylor CB, Kraemer HC, Southam MA, Schneider JA. Relaxation training for essential hypertension at the worksite: II. The poorly controlled hypertensive. Psychosom Med 1987; 49:264-273.
66. Chesney MA, Black GW, Swan GE, Ward MM. Relaxation training for essential hypertension at the worksite: I. The untreated mild hypertensive. Psychosom Med 1987; 49:250-263.
67. Crowther JH. Stress management training and relaxation imagery in the treatment of essential hypertension. J Behav Med 1983; 6:169-187.
68. Hatch JP, Klatt KD, Supik JD, Rios N, Fisher JG, Bauer RL, et al. Combined behavioral and pharmacological treatment of essential hypertension. Biofeedback Self Regul 1985; 10:119-138.
69. Taylor CB, Farquhar JW, Nelson E, Agras S. Relaxation therapy and high blood pressure. Arch Gen Psychiatry 1977; 34:339-342
70. Aivazyan TA, Zaitsev VP, Yurenev AP. Autogenic training in the treatment and secondary prevention of essential hypertension: fiveyear follow-up. Health Psychol 1988; 7 (Suppl):201-208.
71. Friedman H, Taub HA. The use of hypnosis and biofeedback procedures for essential hypertension. Int J Clin Exp Hypn 1977; 25:335-347.
72. Friedman H, Taub HA. A six-month follow-up of the use of hypnosis and biofeedback procedures in essential hypertension. Am J Clin Hypn 1978; 20:184-188.
73. Kuang AK, Wang CX, Li G, Xu DH, Qian YS, Huang ML. Effect of Qigong therapy on plasma 18-OH-DOC level in hypertensives. J Tradit Chin Med 1987; 7:169-170.
74. Patel C, Marmot MG, Terry DJ. Controlled trial of biofeedback-aided behavioural methods in reducing mild hypertension. Br Med J (Clin Res Ed) 1981; 282:2005-2008.
75. Patel C, Marmot MG, Terry DJ, Carruthers M, Hunt B, Patel M. Trial of relaxation in reducing coronary risk: four year follow up. Br Med J (Clin Res Ed) 1985; 290:1103-1106.
76. Gulliksson M, Burell G, Vessby B, Lundin L, Toss H, Svardsudd K. Randomized controlled trial of cognitive behavioral therapy vs. standard treatment to prevent recurrent cardiovascular events in patients with coronary heart disease: Secondary Prevention in Uppsala Primary Healthcare Project (SUPRIM). Arch Intern Med 2011; 171:134-140.
77. Institut für Gesundheitsökonomie und Klinische Epidemiologie (IGKE). International erfolgreiche Interventionen der Prävention und ihre Ü bertragbarkeit auf Deutschland. 2007. http://www. boeckler.de/pdf/pm-2007-10-22-praevention.pdf. [cited 20 April 2011]
78. Higgs J, Jones M. Clinical decision making and multiple problem spaces. In Higgs J, Loftus JM, Christensen SN, editors. Clinical reasoning in the health professions (textbook). Sydney: Butterworth-Heinemann Elsevier; 2008. pp. 3-18.
79. Prochaska JO, Diclemente CC. Self change processes, self efficacy and decisional balance across five stages of smoking cessation. In: Engstrom PF, Anderson PN, Mortenson LEE, editors. Advances in cancer control: epidemiology and research. New York: Alan R. Liss, Inc; 1984. pp. 131-140.
80. Rogers RW. A protection motivation theory of fear appeals and attitude change1. J Psychol 1975; 91:93-114.